Mehdi Moslemi-Kebria, MD
Gynecologic Oncology · Upland, CANPI 1558569830
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $179,020 of the $225,397 with a category attached, or 79.4%. 8 manufacturers reported payments, led by AstraZeneca at 36.5% of the total. Reporting peaked in 2019 at $49,908 and has fallen 81.5% since, to $9,210 in 2025. Among gynecologic oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $1482.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$82K
- GSK$75K
- Intuitive Surgical$35K
- Tesaro, Inc.$26K
- Merck$7K
- Dysis Medical, Inc.$124
- plus $72 from 2 others
What the payments were for
- Consulting fees$2,0551%
- Speaking & faculty fees$179,02079%
- Travel & lodging$4,5622%
- Food & beverage$5,6683%
- Education$34,09215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $82,209 |
| GSK | 46 | $74,684 |
| Intuitive Surgical | 17 | $35,140 |
| Tesaro, Inc. | 30 | $26,411 |
| Merck | 7 | $6,756 |
| Dysis Medical, Inc. | 1 | $124 |
| Clovis Oncology, Inc. | 1 | $52 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$93,309
- LYNPARZA$88,265
- Da Vinci Surgical System$35,050
- JEMPERLI$6,515
- DYSIS Ultra 2.0$124
- DYSIS v3 Digital Coploscope$124
- DYSIS VIEW$124
- CALQUENCE$118
How this compares
$225,397 in reported general payments places this provider in the 95th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $218 |
| Ibuprofen | 23 | $156 |
| Levofloxacin | 36 | $120 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Upland
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Amer KaramStanford$168K
- Rebecca BrooksSacramento$133K
- Kenneth KimWest Hollywood$88K
- Oliver DorigoStanford$85K
- James LiljaCampbell$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.